Vilazodone for the treatment of depression;La vilazodona en el tratamiento de depresión

Annals of Pharmacotherapy

Volumn 45, Issue 7-8, 2011, Pages 946-953

  Lindsey, Wesley T ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

Depression; EMD 68843; Major depressive disorder; Vilazodone

Indexed keywords

BIOLOGICAL MARKER; FLUOXETINE; VILAZODONE;

ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL GLOBAL IMPRESSION SCALE; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG INFORMATION; DRUG MANUFACTURE; DRUG MECHANISM; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; HAMILTON SCALE; HUMAN; INSOMNIA; LETHARGY; MAJOR DEPRESSION; MEDICAL LITERATURE; MEDLINE; MONTGOMERYAASBERG DEPRESSION RATING SCALE; NAUSEA; PATENT; PATIENT COUNSELING; PRIORITY JOURNAL; PSYCINFO; REM SLEEP; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VOMITING; WEB BROWSER;

ADULT; ANIMALS; ANTIDEPRESSIVE AGENTS; BENZOFURANS; DEPRESSIVE DISORDER, MAJOR; GENETIC MARKERS; HUMANS; INDOLES; PIPERAZINES; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 79960811576     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P772     Document Type: Article

References (38)

1. Strine T, Mokdad A, Balluz L, et al. Depression and anxiety in the United States: findings from the 2006 behavioral risk factor surveillance system. Psychiatr Serv 2008;59:1383-90.
2. Kessler R, Berglund P, Demler O, Jin R, Kortez D, Merikkangas K. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication. JAMA 2003;289:3095-105.
3. Perovic B, Jovanovic M, Miljkovic B, Vezmar S. Getting the balance right: established and emerging therapies for major depressive disorders. Neuropsychiatr Dis Treat 2010;6:343-64.
4. Israel J. Remission in depression: definition and initial treatment approaches. J Psychopharmacol 2006;20:5-10.
5. Zimmerman M, Chelminski I, Posternak M. A review of studies of the Montgomery-Asberg Depression Rating Scale in controls: implications for the definition of remission in treatment studies of depression. Int Clin Psychopharmacol 2004;19:1-7.
6. Nierenberg AA, Wright EC. Evolution of remission as the new standard in the treatment of depression. J Clin Psychiatry 1999;60(S22):7-11.
7. Prien R, Carpenter L, Kupfer D. The definition and operational criteria for treatment outcome of major depressive disorder: a review of the current research literature. Arch Gen Psychiatry 1991;48:796-800.
8. Hawley CJ, Gale TM, Sivakumaran T. Defining remission by cut off score on the MADRS: selecting the optimal value. J Affect Disord 2002; 72:177-84.
9. Zimmerman M, McGlinchey J, Michael P, Freidman M, Attiullah N. How should remission from depression be defined? The depressed patient's perspective. Am J Psychiatry 2006;163:148-50.
10. Thase M, Entsuah AR, Rudolph R. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-41.
11. Keller MB, McCollough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000;342:1462-70.
12. Rush AJ, Trivedi MH, Wisniewski SR, et al. Buproprion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006; 354:1231-42.
13. Mallinckrodt CH, Goldstein DJ, Detke MJ, Lu Y, Watkin JG, Tran PV. Duloxetine: a new treatment for the emotional and physical symptoms of depression. J Clin Psychiatry 2003;5:19-28.
14. Gelenberg AJ, Freeman MP, Markowitz JC, et al. Practice guideline for the treatment of patients with major depressive disorder. November 2010. www.psychiatryonline.com/pracGuide/pracGuideChapToc_7.aspx (accessed 2011 Jan 8).
15. Form 8-K: Clinical Data, Inc., report no. 000-12716. Washington, DC: Securities and Exchange Commission, 2011.
16. Khan A. Vilazodone, a novel duel-acting serotonergic antidepressant for managing major depression. Exp Opin Investig Drugs 2009;18:1753-64.
17. Rickels K, Athanasiou M, Reed C. Vilazodone, a novel, duel-acting antidepressant: current status, future promise and potential for individualized treatment of depression. Per Med 2009;6:217-24.
18. Roberts C, Hagan JJ, Bartoszyk GD, Kew JN. Effect of vilazodone on 5- HT efflux and re-uptake in the guinea-pig dorsal raphe nucleus. Eur J Pharmacol 2005;517:59-63.
19. Hughes ZA, Starr KR, Langmead CJ, et al. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol 2005;510:49-57.
20. Bartoszyk GD, Hegenbart R, Ziegler H. EMD 68843. a serotonin reuptake inhibitor with selective presynaptic 5-HT1A receptor agonistic properties. Eur J Pharmacol 1997;322:147-53.
21. Page ME, Cryan JF, Sullivan A, et al. Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran- 2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist. J Pharmacol Exp Ther 2002;302:1220-7.
22. Celada P, Puig MV, Amargos-Bosch M, Adell A, Artigas F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 2004;29:252-65.
23. Dawson LA, Watson JM. Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders. CNS Neurosci Ther 2009;15:107-17.
24. Product information. Viibryd (vilazodone). New Haven, CT: Trovis Pharmaceuticals, LLC, January 2011.
25. Rickels K, Athanasiou M, Robinson D, Gibertini M, Whalen H, Reed C. Evidence for efficacy and tolerability of vilazadone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70:326-33.
26. Khan A, Khan S, Walens G, et al. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the Food and Drug Administration summary basis of approval reports. Neuropsychopharmacol 2003;28:552-7.
27. Storosum J, Elferink A, van Zwieten B, et al. Natural course and placebo response in short-term, placebo-controlled studies in major depression: a meta-analysis of published and non-published studies. Pharmacopsychiatry 2004;37:32-6.
28. Kennedy S, Anderson H, Lam R. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 2006;31:122-31.
29. National Institutes of Health. A one year open label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. www.clinicaltrials.gov/ct2/show/NCT00644358?term=vilazodone&rank=1 (accessed 2010 Nov 22).
30. Robinson D, Kajdasz D, Gallipoli S, Whalen H, Wamil A. A 1-year open label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. Presented at: 163rd Annual Meeting of the American Psychiatric Association, New Orleans, LA, May 22-26, 2010.
31. National Institutes of Health. Effectiveness study of vilazodone to treat depression and to discover genetic markers associated with response. http://www.clinicaltrials.gov/ct2/show/NCT00644358?term=vilazodone&rank=3 (accessed 2010 Nov 22).
32. National Institutes of Health. Safety and efficacy study of vilazodone and discovering genetic markers associated with response in patients with major depressive disorder. www.clinicaltrials.gov/ct2/show/NCT00644358?term=vilazodone&rank=2 (accessed 2010 Nov 22).
33. Ray T. Clinical data to submit vilazodone NDA without PGx marker; reports 11 percent revenue growth in q3. Pharmacogenomics reporter. www.genomeweb.com/dxpgx/clinical-data-submit-vilazodone-nda-without-pgx-marker-reports-11-percent-revenu (accessed 2011 Feb 6).
34. Clayton A, Montejo A. Major depressive disorder, antidepressants, and sexual dysfunction. J Clin Psychiatry 2006;67(S6):33-7.
35. Clayton A, Pradko J, Croft H, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002;63:357-66.
36. Murck H, Frieboes RM, Antonijevic IA, Steiger A. Distinct temporal pattern of the effects of the combined serotonin-reuptake inhibitor and 5- HT1A agonist EMD 68843 on the sleep EEG in healthy men. Psychopharmacol 2001;155:187-92.
37. Morganroth J, Thorn M, Gallipoli S, Sperry V. An evaluation of the effect of vilazodone on cardiac safety. Presented at: American Society of Health-System Pharmacy Midyear Clinical Meeting and Exihibition, Anaheim, CA, Dec 5-9, 2010.
38. Nassar AF, Hollenberg PF, Scatina J, eds. Drug metabolism handbook: concepts and applications. Hoboken, NJ: John Wiley and Sons, 2009.